Cyclo Historical Balance Sheet
| CYTH Stock | USD 0.62 0.01 1.64% |
Trend analysis of Cyclo Therapeutics balance sheet accounts such as Short Long Term Debt Total of 1.2 M, Total Current Liabilities of 8.9 M or Total Stockholder Equity of 2.6 M provides information on Cyclo Therapeutics' total assets, liabilities, and equity, which is the actual value of Cyclo Therapeutics to its prevalent stockholders. By breaking down trends over time using Cyclo Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Cyclo Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cyclo Therapeutics is a good buy for the upcoming year.
Cyclo Therapeutics Inventory |
|
Cyclo |
About Cyclo Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Cyclo Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Cyclo Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Cyclo Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Cyclo currently owns. An asset can also be divided into two categories, current and non-current.
Cyclo Therapeutics Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Cyclo Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cyclo Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Accumulated Other Comprehensive Income
Gains and losses not included in net income that are recorded in shareholders' equity, reflecting changes in the value of assets or liabilities that are not realized.Most accounts from Cyclo Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Cyclo Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.As of now, Cyclo Therapeutics' Accounts Payable is increasing as compared to previous years. The Cyclo Therapeutics' current Cash is estimated to increase to about 9.7 M, while Total Stockholder Equity is projected to decrease to under 2.6 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 171.0K | 1.0M | 1.2M | 1.2M | Total Assets | 19.5M | 4.2M | 13.2M | 13.9M |
Cyclo Therapeutics balance sheet Correlations
Click cells to compare fundamentals
Cyclo Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cyclo Therapeutics balance sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 4.1M | 14.2M | 19.5M | 4.2M | 13.2M | 13.9M | |
| Total Current Liabilities | 3.1M | 3.7M | 3.8M | 3.5M | 8.5M | 8.9M | |
| Total Stockholder Equity | 936.0K | 10.5M | 15.7M | 734.5K | 4.8M | 2.6M | |
| Property Plant And Equipment Net | 64.6K | 87.9K | 77.2K | 56.7K | 929.3K | 505.7K | |
| Net Debt | (2.7M) | (12.7M) | (16.4M) | (1.5M) | (8.2M) | (7.8M) | |
| Retained Earnings | (25.1M) | (34.1M) | (48.3M) | (63.8M) | (83.9M) | (79.7M) | |
| Accounts Payable | 3.1M | 3.5M | 3.7M | 2.2M | 4.9M | 5.1M | |
| Cash | 2.8M | 12.8M | 16.6M | 1.5M | 9.2M | 9.7M | |
| Non Current Assets Total | 155.2K | 137.7K | 84.5K | 56.7K | 929.3K | 694.6K | |
| Non Currrent Assets Other | 90.6K | 49.8K | 7.3K | (56.7K) | 38.3K | 36.4K | |
| Cash And Short Term Investments | 2.8M | 12.8M | 16.6M | 1.5M | 9.2M | 9.7M | |
| Net Receivables | 182.5K | 111.8K | 539.1K | 55.0K | 122.4K | 105.2K | |
| Common Stock Shares Outstanding | 1.1M | 1.6M | 6.4M | 8.4M | 16.3M | 17.1M | |
| Liabilities And Stockholders Equity | 4.1M | 14.2M | 19.5M | 4.2M | 13.2M | 13.9M | |
| Non Current Liabilities Total | 36.1K | 62.9K | 18.0K | 3.5M | 22.5K | 21.4K | |
| Inventory | 242.6K | 237.9K | 227.4K | 254.5K | 254.4K | 250.7K | |
| Other Current Assets | 749.2K | 854.4K | 2.1M | 4.6M | 2.7M | 2.8M | |
| Other Stockholder Equity | 26.0M | 44.5M | 64.0M | 64.5M | 88.6M | 93.0M | |
| Total Liab | 3.2M | 3.7M | 3.8M | 3.5M | 8.5M | 8.9M | |
| Total Current Assets | 4.0M | 14.1M | 19.4M | 4.2M | 12.3M | 12.9M | |
| Common Stock | 12.2K | 477.0 | 841.0 | 849.0 | 2.9K | 3.7K | |
| Net Tangible Assets | 936.0K | 10.5M | 15.7M | 734.5K | 844.7K | 802.5K | |
| Other Assets | 129.7K | 90.6K | 49.8K | 7.3K | 6.6K | 6.2K | |
| Property Plant Equipment | 64.6K | 87.9K | 77.2K | 56.7K | 65.2K | 56.7K | |
| Net Invested Capital | 936.0K | 10.6M | 15.8M | 734.5K | 4.8M | 5.5M | |
| Property Plant And Equipment Gross | 64.6K | 87.9K | 159.3K | 158.2K | 1.1M | 1.1M | |
| Net Working Capital | 816.9K | 10.4M | 15.6M | 677.9K | 3.9M | 5.2M | |
| Capital Stock | 12.2K | 477.0 | 841.0 | 849.0 | 2.9K | 3.5K |
Currently Active Assets on Macroaxis
When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.051 | Return On Assets (2.82) | Return On Equity (226.64) |
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.